Coping strategies, anxiety and depression related to the COVID-19 pandemic in lung transplant candidates and recipients. Results from a monocenter series
- PMID: 34371237
- PMCID: PMC8260501
- DOI: 10.1016/j.resmer.2021.100847
Coping strategies, anxiety and depression related to the COVID-19 pandemic in lung transplant candidates and recipients. Results from a monocenter series
Abstract
Background: The COVID-19 pandemic has been associated with an increase in anxiety and depression symptoms in people. We investigated the impact of the pandemic on coping strategies and anxiety and depression in lung transplantation (LT) recipients and patients with end-stage chronic lung disease awaiting LT.
Methods: We retrospectively investigated coping strategies by using the Coping Inventory for Stressful Situations questionnaire and anxiety and depression symptoms by the Hospital Anxiety and Depression scale in 115 LT candidates and recipients.
Results: Overall, 63 participants (20 women; median age 59 years [interquartile range 52•65]) answered one or both questionnaires (49 LT recipients and 14 LT candidates). The preferred coping strategy was task-focused for 51 (86.4%) participants, with no difference between LT recipients and candidates nor according to the main anamnestic and clinical data. Eleven patients had suspected or proven depression symptoms, and 18 had suspected or proven anxiety symptoms. Coping strategies related to COVID-19 did not differ by presence of anxiety or depression symptoms.
Conclusion: In the current pandemic, healthcare professionals should consider these results to provide relevant psychological help to these fragile populations and promote a systematic and wide multidisciplinary assessment of LT recipients and candidates.
Keywords: Anxiety; COVID-19; Coping strategy; Depression; Lung transplantation.
Copyright © 2021 SPLF and Elsevier Masson SAS. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest CG received speaker fees and travel support from Pfizer, MSD; fees for board memberships from SOS Oxygène and Pulmatrix; grant support from Ohre Pharma, Pfizer, MSD, SOS Oxygène, ISIS Medical, and AstraZeneca. HM reports grants from Pfizer, and fees from Novartis, and Boehringer. JM received congress reimbursement fees from CSLBehring and Fisher&Paykel.
Figures

References
-
- Messika J., Eloy P., Roux A., et al. COVID-19 in lung transplant recipients. Transplantation. 2021;105:177–186. - PubMed
-
- Covid-19 : une enquête pour suivre l tm)èc)volution des comportements et de la santèc) mentale pendant l tm)èc)pidèc)mie. Santèc) Publique France,https://www.santepubliquefrance.fr/etudes-et-enquetes/covid-19-une-enque... (accessed 12 October 2020).
-
- Courtwright A.M., Salomon S., Lehmann L.S., et al. The association between mood, anxiety and adjustment disorders and hospitalization following lung transplantation. Gen Hosp Psychiatry. 2016;41:1–5. - PubMed
-
- Yohannes A.M., Baldwin R.C., Connolly M.J. Depression and anxiety in elderly outpatients with chronic obstructive pulmonary disease: prevalence, and validation of the BASDEC screening questionnaire. Int J Geriatr Psychiatry. 2000;15:1090–1096. - PubMed
-
- Courtwright A.M., Salomon S., Lehmann L.S., et al. The effect of pretransplant depression and anxiety on survival following lung transplant: a meta-analysis. Psychosomatics. 2016;57:238–245. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical